BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/2/2026 7:26:01 AM | Browse: 64 | Download: 215
 |
Received |
|
2025-09-16 09:21 |
|
Peer-Review Started |
|
2025-09-16 09:21 |
|
First Decision by Editorial Office Director |
|
2025-10-13 09:07 |
|
Return for Revision |
|
2025-10-13 09:07 |
|
Revised |
|
2025-10-31 06:43 |
|
Publication Fee Transferred |
|
2025-11-04 03:31 |
|
Second Decision by Editor |
|
2025-12-11 02:39 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-12-11 11:12 |
|
Articles in Press |
|
2025-12-11 11:12 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-01-26 01:45 |
|
Publish the Manuscript Online |
|
2026-02-02 07:26 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
Synergistic antitumor effect of oroxylin A and donafenib in hepatocellular carcinoma through tumor protein p53 signaling pathway activation
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Mei-Yuan Zhang, Rui-Qian Sun, Qi Min, Yu-Qi Zhu, Shu-Kui Qin and Qing-Long Guo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mei-Yuan Zhang, Intensive Care Unit, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine/Shanghai Key Laboratory of Embryo Original Disease, Shanghai Municipal Key Clinical Specialty, No. 1567 Jinqian Road, Fengxian District, Shanghai 201499, China. zhangmeiyuan1972@163.com |
| Key Words |
Hepatocellular carcinoma; Oroxylin A; Donafenib; Combination therapy; Xenograft tumor; TP53 signaling pathway |
| Core Tip |
This study demonstrates that the combination of oroxylin A and donafenib exerts a potent synergistic antitumor effect against hepatocellular carcinoma in vitro and in vivo. Mechanistically, this synergy is achieved through the convergent activation of the tumor-suppressive tumor protein p53 signaling pathway. This work provides a novel and effective therapeutic strategy for hepatocellular carcinoma. |
| Publish Date |
2026-02-02 07:26 |
| Citation |
Zhang MY, Sun RQ, Min Q, Zhu YQ, Qin SK, Guo QL. Synergistic antitumor effect of oroxylin A and donafenib in hepatocellular carcinoma through tumor protein p53 signaling pathway activation. World J Gastroenterol 2026; 32(6): 113529 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i6/113529.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i6.113529 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
